New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
07:57 EDTVRXValeant sees FY13 impact from generics >$100M in revenues
Sees $40M-$50M in revenue declines as a result of planned divestitures. Sees Efinaconazole launch breakeven in 2013. Sees FY13 Solodyn revenue $250M-$275M.
News For VRX From The Last 14 Days
Check below for free stories on VRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
07:08 EDTVRXDrug deals increase to new high, Bloomberg says
M&A activity in the specialty pharmaceuticals industry has reached a new high after Mallinckrodt (MNK) recently bought Questcor (QCOR) for $5.6B, reported Bloomberg. Drugmakers from Actavis (ACT) to Valeant (VRX) are widening their suites of drugs through takeovers that immediately increased earnings with the help of lower corporate tax rates in countries such as Ireland. Reference Link
April 7, 2014
14:09 EDTVRXSun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use